Fred M. Teskin

Array ( [id] => 13153995 [patent_doc_number] => 10093709 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => GM-CSF and IL-4 conjugates, compositions, and methods related thereto [patent_app_type] => utility [patent_app_number] => 15/491777 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 52 [patent_no_of_words] => 23763 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15491777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13153997 [patent_doc_number] => 10093710 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia [patent_app_type] => utility [patent_app_number] => 15/485093 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 14929 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15485093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12322776 [patent_doc_number] => 09943567 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-17 [patent_title] => Method for treating arthritis using IK factor or nucleic acid encoding IK factor [patent_app_type] => utility [patent_app_number] => 15/481787 [patent_app_country] => US [patent_app_date] => 2017-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 29 [patent_no_of_words] => 20032 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15481787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12177443 [patent_doc_number] => 20180036379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'Method of Treating Psoriasis with Increased Interval Dosing of Anti-IL12/23 Antibody' [patent_app_type] => utility [patent_app_number] => 15/471790 [patent_app_country] => US [patent_app_date] => 2017-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 40873 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15471790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743964 [patent_doc_number] => 20170198035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders' [patent_app_type] => utility [patent_app_number] => 15/466128 [patent_app_country] => US [patent_app_date] => 2017-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 59263 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15466128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14075009 [patent_doc_number] => 20190086392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => METHODS FOR DIAGNOSIS AND TREATMENT OF SOLAR LENTIGO [patent_app_type] => utility [patent_app_number] => 16/086337 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12546318 [patent_doc_number] => 10011647 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-03 [patent_title] => IL-33 antagonists and uses thereof [patent_app_type] => utility [patent_app_number] => 15/463910 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13680 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15463910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969920 [patent_doc_number] => 20170274073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/448437 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 48113 [patent_no_of_claims] => 73 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15448437 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11704616 [patent_doc_number] => 20170173115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'MACROPHAGE ACTIVATING FACTOR FOR PHARMACEUTICAL COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/444199 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6404 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15444199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929111 [patent_doc_number] => 20190048071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => ANTIBODIES FOR IL-17C [patent_app_type] => utility [patent_app_number] => 16/076401 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15753741 [patent_doc_number] => 10618966 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Methods for the treatment of interleukin-6 receptor-related diseases and disorders [patent_app_type] => utility [patent_app_number] => 15/434224 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 70 [patent_no_of_words] => 76141 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 244 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15434224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627336 [patent_doc_number] => 20170137526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'USE OF INTERLEUKIN-4 ANTAGONISTS AND COMPOSITIONS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/414447 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 26146 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11662605 [patent_doc_number] => 20170151311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'Method of treating dyspnea associated with acute heart failure' [patent_app_type] => utility [patent_app_number] => 15/412447 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 27510 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253533 [patent_doc_number] => 20200262907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => CCL20 AS A PREDICTOR OF CLINICAL RESPONSE TO IL23-ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/063803 [patent_app_country] => US [patent_app_date] => 2016-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16063803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060158 [patent_doc_number] => 11104745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/062096 [patent_app_country] => US [patent_app_date] => 2016-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 52 [patent_no_of_words] => 54364 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 277 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16062096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14883565 [patent_doc_number] => 10421809 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Anti-TLR4 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/370466 [patent_app_country] => US [patent_app_date] => 2016-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 11167 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15370466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992400 [patent_doc_number] => 20170296555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE' [patent_app_type] => utility [patent_app_number] => 15/369056 [patent_app_country] => US [patent_app_date] => 2016-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 57137 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15369056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12962680 [patent_doc_number] => 09873743 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-23 [patent_title] => IL3Ra antibody conjugates and uses thereof [patent_app_type] => utility [patent_app_number] => 15/342668 [patent_app_country] => US [patent_app_date] => 2016-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 33 [patent_no_of_words] => 71449 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15342668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12565986 [patent_doc_number] => 10017569 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection [patent_app_type] => utility [patent_app_number] => 15/334542 [patent_app_country] => US [patent_app_date] => 2016-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6403 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15334542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11820606 [patent_doc_number] => 20170209542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29' [patent_app_type] => utility [patent_app_number] => 15/294153 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46241 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15294153 [rel_patent_id] =>[rel_patent_doc_number] =>)